Plague is a life-threatening zoonotic disease caused by *Yersinia pestis*. Zoonotic foci exist on several continents; however, resource-poor areas in sub-Saharan Africa account for most human cases ([@R1]). The pathogenesis of plague involves facultative intracellular infection of host macrophages, followed by fulminant extracellular growth and bacteremia ([@R2]). In the absence of effective antimicrobial drug treatment, bubonic plague is fatal in ≈50% of cases and pneumonic plague in \>90% ([@R1],[@R3]).

Drugs approved by the US Food and Drug Administration (FDA) for treatment of plague include streptomycin and doxycycline. Streptomycin is bactericidal but rarely used because of limited availability and serious toxicities. Doxycycline is bacteriostatic and lacks concentration-dependent activity or a postantibiotic effect, which might limit its efficacy for serious *Y. pestis* infections ([@R4]). Nevertheless, low cost and oral dosing have made doxycycline a first-line treatment in several countries ([@R5],[@R6]). Fluoroquinolones, include ciprofloxacin, have recently been approved by the FDA for treatment of plague based on animal and in vitro studies ([@R4],[@R7],[@R8]). Clinical experience with these agents, however, is limited ([@R1],[@R5]).

During 2011--2014, patients with suspected plague seen at 6 clinics and 2 hospitals in the West Nile region of Uganda were offered enrollment in an open-label study evaluating the safety and efficacy of ciprofloxacin for treatment of plague. Patients were excluded if they were pregnant, \<8 years of age, considered too ill to receive oral treatment, or had received antimicrobial drug treatment in the preceding 7 days. After written consent was obtained, diagnostic samples were collected and oral ciprofloxacin administered for 10 days at a weight-calibrated dosage of ≈15 mg/kg twice daily (range 13--17 mg/kg), with a maximum dose for adults of 750 mg twice daily. Diagnostic samples were cultured on sheep blood agar and suspect isolates confirmed by bacteriophage lysis ([@R9]). Patients were monitored daily during treatment, and clinical outcome was assessed 14--21 days after initial evaluation. Because of simultaneous prevention efforts and lower than expected enrollment, the study was terminated early. The study was approved by Institutional Review Boards at the Uganda Virus Research Institute, the Uganda National Council for Science and Technology, and the US Centers for Disease Control and Prevention.

Five patients with culture-confirmed plague were enrolled and treated with oral ciprofloxacin ([Table](#T1){ref-type="table"}). Median patient age was 27 years (range 10--52 years); median time between illness onset and enrollment was 4 days (range 1--7 days). Four patients had bubonic plague, with *Y. pestis* isolated from bubo aspirates or blood cultures. The fifth patient, a 13-year-old boy, had pneumonic plague as indicated by hemoptysis, patchy bilateral infiltrates on chest radiograph, and *Y. pestis* isolated from sputum. The illness had evolved over 6 days, a clinical course suggestive of secondary rather than primary pneumonic plague ([@R3]); the primary focus of infection was not identified.

###### Demographic and clinical characteristics of 5 patients with culture-confirmed plague (*Yersina pestis* infection) who were treated successfully with oral ciprofloxacin, Uganda, 2011--2014

  Patient no.   Age, y/sex   Length of illness, d\*   Symptoms                                        Laboratory evidence                               Ciprofloxacin dose, mg†
  ------------- ------------ ------------------------ ----------------------------------------------- ------------------------------------------------- -------------------------
  1             10/F         7                        Fever, left axillary bubo                       Bubo, blood cultures positive                     250
  2             52/F         4                        Fever, right axillary bubo                      Bubo, blood cultures positive                     650
  3             27/F         1                        Fever, left inguinal bubo                       Bubo, blood cultures positive                     750
  4             36/M         1                        Fever, left axillary bubo                       Blood culture positive                            625
  5             13/M         6                        Fever, chest pain, cough, blood-tinged sputum   Sputum culture positive, blood culture negative   375

\*At time treatment was sought. †Orally, twice daily; ≈15 mg/kg bodyweight with a maximum of 750 mg.

Three patients were admitted and 2 treated as outpatients. In addition to ciprofloxacin, all received acetaminophen, and 2 received a bolus of normal saline. All became afebrile within 2 days. At 14 days, all had been discharged and returned to their normal activities. The 13-year-old boy with culture-confirmed pneumonic plague reported mild, nonproductive cough, but no complications were identified.

Fluoroquinolones have pharmacokinetic properties that make them attractive for treatment of plague, including bactericidal activity, good oral bioavailability, excellent tissue penetration, and an established safety record ([@R8],[@R10]). In vitro assays suggest that ciprofloxacin is comparable to streptomycin and superior to doxycycline or gentamicin for killing of intracellular *Y. pestis* ([@R4]), and efficacy has been demonstrated in rodent and nonhuman primate models ([@R8]). Along with FDA approval, our results add to growing clinical experience ([@R5]) and support the broader use of oral ciprofloxacin for treatment of human plague, especially in resource-poor areas where intravenous treatment is limited.
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